From PsychonautWiki
(Redirected from MPA)
Jump to navigation Jump to search
Summary sheet: Methiopropamine
Chemical Nomenclature
Common names MPA
Substitutive name Methiopropamine
Systematic name 1-(Thiophen-2-yl)-2-methylaminopropane
Class Membership
Psychoactive class Stimulant
Chemical class Thiophene
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 10 mg
Light 20 - 30 mg
Common 30 - 50 mg
Strong 50 - 60 mg
Heavy 60 mg +
Total 6 - 10 hours
Onset 30 - 60 minutes
Peak 2 - 4 hours
Offset 2 - 3 hours
After effects 1 - 2 hours

Threshold 5 mg
Light 5 - 20 mg
Common 20 - 40 mg
Strong 40 - 60 mg
Heavy 60 mg +
Total 2 - 4 hours
Onset 5 - 10 minutes
Come up 5 - 10 minutes
Peak 30 - 60 minutes
Offset 30 - 120 minutes
After effects 6 - 8 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


Methiopropamine (also known as MPA) is a stimulant substance of the thiophene class. It is a ring-based structural analogue of methamphetamine.

Methiopropamine was first synthesized in 1942.[1] It appeared for public sale in the U.K. in December 2010 as a research chemical or legal high, recently branded as "Blow".[2]

Subjective effects are reportedly similar to those of classical stimulants and includes stimulation, focus enhancement, motivation enhancement, increased libido, appetite suppression, and euphoria. However, it is generally considered to be as euphoric or recreational as classical stimulants. It is occasionally reported to be used as a study aid.

Limited data exists about the pharmacology and toxicity of methiopropamine in humans, and it has only a short history of human use. It is highly advised to use harm reduction practices if using this substance.


Methiopropamine, or 1-(thiophen-2-yl)-2-methylaminopropane, is a synthetic molecule of the thiophene class. It is a structural analogue to methamphetamine. It contains a thiophene ring bound to an amino (NH2) group through an ethyl chain with an additional methyl substitution at Rα. Methiopropamine contains an additional methyl substitution at RN (similarly to MDMA and methamphetamine). Although methiopropamine is analogous to methamphetamine, it is neither an amphetamine nor a phenethylamine as methiopropamine contains a thiophene ring instead of a benzene ring. Thiophene is a five-membered aromatic ring with a sulphur constituent.


Methiopropamine functions as a selective norepinephrine-dopamine releasing agent. This allows dopamine and norepinephrine to accumulate within the brain, resulting in stimulating and euphoric effects. It is approximately one third as potent as dextroamphetamine as a norepinephrine reuptake inhibitor and one fifth as much as a dopamine reuptake inhibitor. It displays negligible activity as a serotonin reuptake inhibitor.[3]

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), a literature which relies on collected anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely with higher doses and may include serious injury or death.

Physical effects

Cognitive effects

After effects
Aftereffects (3).svg

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential


This toxicity and harm potential section is a stub.

As such, it may contain incomplete or even dangerously wrong information. You can help by expanding or correcting it.
We also recommend that you conduct independent research and use harm reduction practices when using this substance.

The toxicity and long-term health effects of recreational MPA use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because MPA has very little history of human usage. Anecdotal evidence from people who have tried MPA within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed).

It is strongly recommended that one use harm reduction practices when using this substance.

Dependence and abuse potential

As with other stimulants, the chronic use of MPA can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of MPA develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). MPA presents cross-tolerance with all dopaminergic stimulants, meaning that after the consumption of MPA all stimulants will have a reduced effect.


Main article: Stimulant psychosis

Abuse of compounds within the stimulant class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, or delusions).[4] A review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely.[5][6] The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.[7]

Dangerous interactions

Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when combined with other substances. The list below includes some known dangerous combinations (although it cannot be guaranteed to include all of them). Independent research (e.g. Google, DuckDuckGo) should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from TripSit.

  • Stimulants - MPA can be potentially dangerous in combination with other stimulants as it can increase one's heart rate and blood pressure to dangerous levels.
  • 25x-NBOMe & 25x-NBOH - Members of the 25x family are highly stimulating and physically straining. Combinations with stimulants should be avoided due to the risk of excessive stimulation. This can result in panic attacks, thought loops, seizures, increased blood pressure, vasoconstriction, and heart failure in extreme cases.
  • Alcohol - Alcohol can be dangerous to combine with stimulants due to the risk of accidental over-intoxication. Stimulants mask the sedative effects of alcohol, which is the main factor people use to assess their degree of intoxication. Once the stimulant wears off, the depressant effects of alcohol are left unopposed, which can result in blackouts and respiratory depression. If combined, one should strictly limit themselves to only drinking a certain amount of alcohol per hour.
  • DXM - Combinations with DXM should be handled with extreme care due to DXM's effects on serotonin and norepinephrine reuptake. This can lead to panic attacks, hypertensive crisis, or serotonin syndrome with stimulants that increase levels of serotonin (MDMA, methylone, mephedrone, etc.). Monitor blood pressure carefully and avoid strenuous physical activity.
  • MDMA - The neurotoxic effects of MDMA may be increased when combined with other stimulants. There is also a risk of excessive heart strain.
  • MXE - Combinations with MXE may dangerously elevate blood pressure and increase the risk of psychosis.
  • Stimulants - Methiopropamine can be potentially dangerous in combination with other stimulants as they can increase one's heart rate and blood pressure to dangerous levels.
  • Cocaine - This combination may increase strain on the heart.
  • Tramadol - Tramadol lowers the seizure threshold.[8] Combinations with stimulants may further increase this risk.

Legal issues

  • Austria: Since June 26, 2019, Methiopropamine is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)[10]
  • China: Methiopropamine is a controlled substance.[11]
  • Finland: Methiopropamine is illegal in Finland.[citation needed]
  • Germany: Methiopropamine is controlled under Anlage I BtMG (Narcotics Act, Schedule I)[12] as of July 17, 2013.[13] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[14]
  • Switzerland: Methiopropamine is a controlled substance specifically named under Verzeichnis D.[15]
  • United Kingdom: Methiopropamine is a Class B drug.[16]
  • United States: Methiopropamine is not scheduled at the federal level in the United States,[17] but it could be considered an analogue of methamphetamine in which case purchase, sale, or possession could be prosecuted under the Federal Analogue Act. Methiopropamine's structure differs from methamphetamine's structure significantly more than previous successful prosecutions under the same law.[citation needed]
    • Florida: Methiopropamine is a Schedule I controlled substance in the state of Florida, making it illegal to buy, sell, or possess in Florida.[18]

See also

External links


  1. α-Thienylaminoalkanes |
  2. The syntheses of 1-(2-thienyl)-2-(methylamino) propane (methiopropamine) and its 3-thienyl isomer for use as reference standards. ( / NCBI) |
  3. Neurochemical profiles of some novel psychoactive substances (ScienceDirect) |
  4. Treatment for amphetamine psychosis | [1]
  5. Treatment for amphetamine psychosis | [2]
  6. Hofmann FG (1983). A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects (2nd ed.). New York: Oxford University Press. p. 329. ISBN 9780195030570.
  7. Treatment for amphetamine psychosis | [3]
  8. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of Medical Toxicology, 5(2), 63-67.
  9. Gillman, P. K. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia, 95(4), 434-441.
  11. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. Archived from the original on February 10, 2017. Retrieved December 28, 2019. 
  12. "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 28, 2019. 
  13. "Siebenundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (in German). Bundesanzeiger Verlag. Retrieved December 18, 2019. 
  14. "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 18, 2019. 
  15. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  16. United Kingdom. (2017). Misuse of Drugs Act 1971 (S.I. 2017/1114). London: The Stationery Office Limited. Retrieved February 9, 2018, from